Automated Breast Ultrasound System (ABUS) is an innovative breast cancer screening device. ABUS technology uses high-frequency sound waves to diagnose cancers and provides the 3-D image of the breasts. It is mainly used to diagnose breast cancer conditions in dense breasts, where breasts have more glandular tissue than fatty tissue. Automated Breast Ultrasound System Market dominated by key players for instance. In June 2014, the U.S. FDA approved General Electric Healthcare’s, Invenia automated breast ultrasound system, a next-generation breast imaging technology to diagnose the breast cancers in dense breasts. In September 2015, GE Healthcare and Symed L.L.C team launched Automated Breast Ultrasound system (ABUS) in Dubai. In February 2014, Philips Healthcare entered a distribution agreement with SonoCine to market its automated whole breast ultrasound (AWBUS) system in the U.S. market.
Automated Breast Ultrasound System Market report gives a comprehensive outlook on global market scenario, growth trends, shares, with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The report gives historical, current, and future market sizes (US$ Mn) on the basis of product type, modality, end user and region. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyze the market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the report include manufacturers, distributors, policy makers, and service providers engaged in Automated Breast Ultrasound System